Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Obtains Manufacturing Patent Zygel

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will now be free to run its Zygel cannabidiol (CBD) cream manufacturing business. This is because it has obtained a US patent for the product.

About Zygel cannabidiol (CBD)

 Zygel cannabidiol (CBD) is a product that will treat a condition known as Fragile X syndrome. This happens to be a genetic condition that results in adverse effects if not treated in good time. Some of the undesirable effects would include developmental issues such as cognitive impairment and learning disabilities.

Zynerba Pharmaceuticals is excited to be at the frontline in helping fight off this condition. It sees the patent as a major incentive as it continues to make more investments in research.

Plans into the future

The expiry date of this patent is 2038 and the company hopes to have made significant business steps by then. This patent is quite elaborate. It caters to the company’s strategy of administering about 250 milligrams to 500 milligrams of CBD transdermally. This will be administered daily and will be in the form of a cream or gel.

Study underway

Much is currently going in terms of analyzing Zygel. For instance, the evaluation is being done with a double-blind placebo-controlled study known as CONNECT-FX. It is a study involving about 204 pediatric Fragile X patients and the company hopes to identify better ways of helping patients.

One of the researchers says that they seek to learn more about the observable changes. This is in line with the checklist for the Fragile X-specific behavior.

A few patients have already completed the double-blind phase. The next step will be for them to again enroll in yet another 12-month open-label phase. If all goes as planned, we should by 2020 anticipate some dependable data.

Scientists have commended the company for its efforts. They say that a condition that could impair learning capabilities and development is detrimental. Though a rare condition, there is a need to fight it off according to scientists.

Zynerba Pharmaceuticals admits that it hasn’t been easy getting to this point. It has been marred by financial and management challenges along the way. However, obtaining this patent is a great relief.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Posts New ZYN002 Data Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Posts Positive Data From Phase ! Trial Of ZYN002 CBD Gel

Pin It on Pinterest